Abstracts tagged "Pediatric rheumatology"

Abstract Number: L22 • 2019 ACR/ARP Annual Meeting
Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study
Hermine Brunner¹, Olga Synoverska ², Tracy Ting ³, Carlos Abud Mendoza ², Alberto Spindler ², Yulia Vyzhga ², Katherine Marzan ³, Vladimir Keltsev ², Irit Tirosh ², Lisa Imundo ³, Rita Jerath ³, Daniel Kingsbury ³, Betul Sozeri ², Sheetal Vora ³, Sampath Prahalad ³, Elena Zholobova ², Yonatan Butbul Aviel ², Vyacheslav Chasnyk ², Melissa Lerman ³, Kabita Nanda ³, Heinrike Schmeling ³, Heather Tory ³, Yosef Uziel ², Diego Oscar Viola ², Holly Posner ⁴, Keith Kanik ⁵, Ann Wouters ⁴, Cheng Chang ⁵, Richard Zhang ⁴, Irina Lazariciu ⁶, Ming-Ann Hsu ⁵, Ricardo Suehiro ⁷, Alberto Martini ², Daniel J. Lovell ³ and Nicolino Ruperto ⁸, ¹PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ⁴Pfizer Inc, New York, New York, ⁵Pfizer Inc, Groton, Connecticut, ⁶IQVIA, Montreal, Quebec, Canada, ⁷Pfizer Inc, Collegeville, Pennsylvania, ⁸PRINTO, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. Here we assess the efficacy and safety of tofacitinib in patients (pts)…
Abstract Number: 799 • 2019 ACR/ARP Annual Meeting
Application of the Autoinflammatory Disease Activity Index (ADDI) to a Cohort of Patients in a Tertiary Hospital
Mireia Lopez-corbeto¹ and Estefania Moreno Ruzafa ¹, ¹Hospital Universitari Vall d'Hebron, Barcelona, Spain
Background/Purpose: Autoinflammatory diseases (AIDs) cause chronic systemic inflammation that can damage multiple organs. Recently, the ADDI index has been developed and validated in the four…
Abstract Number: 2251 • 2019 ACR/ARP Annual Meeting
Understanding Vulnerabilities in Diagnosis and Care of Childhood and Adult-Onset Lupus: A Qualitative Study
Siobhan Case¹, Corine Sinnette ², Courtnie Phillip ², Claire Grosgogeat ³, Karen Costenbader ², Cianna Leatherwood ⁴, Candace Feldman ² and Mary Beth Son ³, ¹Brigham and Women's Hospital and Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Kaiser Permanente, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) poses complex diagnostic and management challenges, which may differ depending on whether SLE was diagnosed in childhood (cSLE) or in…
Abstract Number: 802 • 2019 ACR/ARP Annual Meeting
Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial
Helen Lachmann¹, Bernard Lauwerys ², Paivi Miettunen ³, Tilmann Kallinich ⁴, Annette Jansson ⁵, Itzhak Rosner ⁶, Raffaele Manna ⁷, Saramaria Murias ⁸, Sinisa Savic ⁹, Serge Smeets ¹⁰, Fabrizio De Benedetti ¹¹ and Anna Simon ¹², ¹The Royal Free Hospital & University College London, London, United Kingdom, ²Université catholique de Louvain, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, ³Alberta Children's Hospital, Calgary, ON, Canada, ⁴Charite, Berlin, Germany, ⁵Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-University, Munich, Germany, ⁶Bnei Tzion, Haifa, Israel, ⁷Università Cattolica del Sacro Cuore, Rome, Lazio, Italy, ⁸University Hospital La Paz, Madrid, Madrid, Spain, ⁹St James’s University Hospital, Leeds, England, United Kingdom, ¹⁰Novartis, Amsterdam, Netherlands, ¹¹Bambino Gesù Children’s Hospital, Rome, Italy, ¹²Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Recurrent fever syndromes have a significant impact on health-related quality of life (HRQoL).1 Canakinumab (CAN) has demonstrated efficacy and safety in patients with colchicine-resistant…
Abstract Number: 2704 • 2019 ACR/ARP Annual Meeting
Injection Fear in Juvenile Idiopathic Arthritis Patients Using Injectable Medications
Kathleen Collins¹, Anava Wren ² and Tzielan Lee ², ¹Stanford University School of Medicine, Palo Alto, CA, ²Stanford University School of Medicine, Palo Alto
Background/Purpose: Injectable medications are frequently used to treat Juvenile Idiopathic Arthritis (JIA). Fear of pain and needle fear have been identified as barriers to injectable…
Abstract Number: 892 • 2019 ACR/ARP Annual Meeting
Adverse Childhood Experiences Are Associated with Systemic Lupus Erythematosus in a Clinical Population from Bronx, New York
Roberto Valdovinos¹, Nicole Brown ², Miguelina Germán ², Qi Gao ³, Kaye Brathwaite ², Kimberly Reidy ², Dawn Wahezi ⁴, Chaim Putterman ⁵, Ruth E. Stein ² and Tamar Rubinstein ⁶, ¹Albert Einstein College of Medicine, Philadelphia, PA, ²Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, ³Albert Einstein College of Medicine, Bronx, ⁴Children’s Hospital at Montefiore, New York, ⁵Albert Einstein College of Medicine, New York, NY, ⁶Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Adverse Childhood Experiences (ACEs), which can result in chronic stress, are associated with autoimmune diseases in adulthood and arthritis in childhood. Recently ACEs were…
Abstract Number: 2707 • 2019 ACR/ARP Annual Meeting
Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study
Hermine Brunner¹, Nikolay Tzaribachev ², Ingrid Louw ³, Jordi Antón ⁴, Diego Viola ⁵, Bernard Lauwerys ⁶, Rubèn J Cuttica ⁷, Pierre Quartier ⁸, Elisabeth Gervais ⁹, Alexandre Belot ¹⁰, Kirsten Minden ¹¹, Thomas Lutz ¹², Rolando Cimaz ¹³, Mahmood M. T. M. Ally ¹⁴, Riana van Zyl ¹⁵, Inmaculada Calvo Penadés ¹⁶, Joe Zhuo ¹⁷, Robert Wong ¹⁸, Marleen Nys ¹⁹, Yedid Elbez ²⁰, Alberto Martini ²¹, Daniel J. Lovell ²² and Nicolino Ruperto ²³, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Panorama Medical Centre, Parow, South Africa, ⁴Hospital Sant Joan de Déu, Barcelona, Spain, ⁵CAICI Institute, Rosario City, Santa Fe State, Argentina, ⁶Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁷Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁸Necker Hospital, Paris, France, ⁹CHU de Poitiers, Rheumatology, Poitiers, France, ¹⁰Centre Hospitalier Universitaire de Lyon, Lyon, France, ¹¹German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ¹²Heidelberg University Hospital, Heidelberg, Germany, ¹³Meyer Children's Hospital in Florence, Florence, Italy, ¹⁴University of Pretoria, Pretoria, South Africa, ¹⁵University of the Free State, Bloemfontein, South Africa, ¹⁶Hospital Univ. La Fe, Valencia, Spain, ¹⁷Bristol-Myers Squibb, Princeton, NJ, ¹⁸Bristol-Myers Squibb, Princeton, ¹⁹Bristol-Myers Squibb, Braine L’Alleud, Belgium, ²⁰Excelya, Boulogne-Billancourt, France, ²¹IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ²²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ²³Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy
Background/Purpose: Efficacy of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label, Phase III international study (NCT01844518).1 Pediatric patient-reported outcomes…
Abstract Number: 1295 • 2019 ACR/ARP Annual Meeting
Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells
Lauren Pachman¹, Wil Marin ², Gabrielle Morgan ¹, Megan L. Curran ³, Kaveh Ardalan ⁴, Chiang-Ching Huang ⁵ and Eli Roberson ⁶, ¹Northwestern University, Chicago, ²Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, IL, ³University of Colorado, Aurora, CO, ⁴Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵University of Milwaukee, Milwaukee, WI, ⁶Washington University at St.Louis, St.Louis, MO
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory myopathy in which the immunoregulatory control is not well understood. Collaboration with A.R. French, MD/PhD, documented the…
Abstract Number: 2710 • 2019 ACR/ARP Annual Meeting
Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study
Fabrizio De Benedetti¹, Inmaculada Calvo Penadés ², Nadina Rubio-Pérez ³, Alexey Maschan ⁴, Pierre Quartier ⁵, Zbigniew Żuber ⁶, Marina Stanislav ⁷, Raul Barria ⁸, Daniel Clemente ⁹, Gabriel Vega-Cornejo ¹⁰, Nancy Liu ¹¹, Christine Xu ¹¹, Angeliki Giannelou ¹², Bolanle Akinlade ¹² and Lydie Baret-Cormel ¹³, ¹Bambino Gesù Children’s Hospital, Rome, Italy, ²Hospital Univ. La Fe, Valencia, Spain, ³University Hospital Dr. José Eleuterio González, Monterrey, Mexico, ⁴Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia, ⁵Necker Hospital, Paris, France, ⁶Andrzej Frycz Modrzewski Krakow University, Kraków, Poland, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸Bioreuma, Concepción, Chile, ⁹Hospital Infantil Universitario Niño Jesús, Madrid, Spain, ¹⁰CREA de Guadalajara, Jalisco, Mexico, ¹¹Sanofi, Bridgewater, NJ, ¹²Regeneron, New York, NY, ¹³Sanofi, Chilly-Mazarin, France
Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to membrane and soluble IL-6 receptor-α. Sarilumab is approved for adults with rheumatoid arthritis (RA) and is being…
Abstract Number: 1724 • 2019 ACR/ARP Annual Meeting
Disease Manifestations and Impact on Quality of Life in Subjects with Pre-Pubertal Onset Systemic Lupus Erythematosus
Brandi Stevens¹, Martha Rodriquez ¹, Amy Rakestraw ² and Kathleen O'Neil ¹, ¹Indiana University, Indianapolis, IN, ²Indiana University Health, Indianapolis, IN
Background/Purpose: Systemic Lupus Erythematosus (SLE) can be a severe disease, especially when diagnosed in childhood. Onset prior to puberty (Tanner stage II) is rare, and…
Abstract Number: 2716 • 2019 ACR/ARP Annual Meeting
Long Term Outcomes of Childhood Onset Rheumatoid Arthritis
Rebecca Overbury¹, Aimee Hersh ², CJ Inman ², Sara Stern ², Karen James ² and John Bohnsack ³, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah School of Medicine, Salt Lake City, UT
Background/Purpose: Childhood onset rheumatoid arthritis (CORA) describes patients with juvenile idiopathic arthritis (JIA) who are rheumatoid factor (RF) or anti-cyclic citrullinated antibody (ACPA) positive. Phenotypically,…
Abstract Number: 1728 • 2019 ACR/ARP Annual Meeting
Persistent Disease Activity Is Associated with Avascular Necrosis Development in Juvenile Systemic Lupus Erythematosus
Anthony Hoang ¹, Howard Yang ², Tracy Andrews ³, Jennifer Weiss ⁴, Kathleen Haines ⁴, Yukiko Kimura ⁵ and Suzanne Li⁴, ¹Rutgers University, New Brunswick, NJ, ²David Geffen School of Medicine at UCLA, Santa Monica, CA, ³Rutgers University, Newark, NJ, ⁴Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ⁵Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH
Background/Purpose: Avascular necrosis (AVN) is a serious comorbidity of juvenile systemic lupus erythematosus (jSLE) associated with disability, impaired quality of life, and increased cost of…
Abstract Number: 2719 • 2019 ACR/ARP Annual Meeting
Predictors of Health Care Transition Practices Among North American Pediatric Rheumatology Providers
Rebecca Sadun¹, Amanda Eudy ¹, Peter Chiraseveenuprapund ², Cuoghi Edens ³, Aimee Hersh ⁴, Kiana Johnson ⁵ and Erica Lawson ⁶, ¹Duke University, Durham, ²UCSD, San Diego, CA, ³University of Chicago, Chicago, IN, ⁴University of Utah, Salt Lake City, UT, ⁵East Tennessee, Johnson City, TN, ⁶University of California San Francisco Benioff Children’s Hospital, San Francisco, CA
Background/Purpose: The transition from pediatric to adult-oriented health care represents a vulnerable period for young adults with chronic rheumatic diseases. In spite of this, a…
Abstract Number: 1746 • 2019 ACR/ARP Annual Meeting
Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers
Elizabeth Sloan¹, Tracey Wright ¹ and Yu Zuo ², ¹University of Texas Southwestern, Texas Scottish Rite Hospital for Children, Children's Health, Dallas, TX, ²University of Texas Southwestern, Dallas, TX
Background/Purpose: Antiphospholipid antibodies (aPL) have been extensively reported in children; however, research on thrombotic risks associated with aPL among pediatric patients is scarce. Positive aPL…
Abstract Number: 2721 • 2019 ACR/ARP Annual Meeting
Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome
Sabrina Gmuca¹, Maitry Sonagra ², Rui Xiao ², Elizabeth Mendoza ², Kimberly S. Miller ³, Nina H. Thomas ¹, Pamela F. Weiss ¹, David D. Sherry ¹ and Jeffrey Gerber ², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³Children's Hospital fo Philadelphia, Philadelphia, PA
Background/Purpose: Dyscognition, including loss of mental clarity and problems with attention and memory, often affects adolescents with juvenile fibromyalgia syndrome (JFMS). Our understanding of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].